373 related articles for article (PubMed ID: 28581874)
1. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective.
Sagar B; Lin YS; Castel LD
J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874
[TBL] [Abstract][Full Text] [Related]
2. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
3. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
4. Medical costs associated with use of systemic therapy in adults with colorectal cancer.
Seal BS; Sullivan SD; Ramsey S; Shermock KM; Ren J; Kreilick C; Foltz Boklage SH; Valluri S; Sarma S; Asche CV
J Manag Care Pharm; 2013; 19(6):461-7. PubMed ID: 23806060
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
6. Estimating Costs of Care Attributable to Cancer: Does the Choice of Comparison Group Matter?
Chen AB; Li L; Cronin AM; Brooks GA; Kavanagh BD; Schrag D
Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):3227-3244. PubMed ID: 28858372
[TBL] [Abstract][Full Text] [Related]
7. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
Kreys ED; Koeller JM
J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
[TBL] [Abstract][Full Text] [Related]
8. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of brain metastasis among lung cancer patients in the United States.
Guérin A; Sasane M; Dea K; Zhang J; Culver K; Nitulescu R; Wu EQ; Macalalad AR
J Med Econ; 2016; 19(5):526-36. PubMed ID: 26735844
[TBL] [Abstract][Full Text] [Related]
10. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
11. Impact of Hospice on Spending and Utilization Among Patients With Lung Cancer in Medicare.
Kalidindi Y; Segel J; Jung J
Am J Hosp Palliat Care; 2020 Apr; 37(4):286-293. PubMed ID: 31564110
[TBL] [Abstract][Full Text] [Related]
12. Modeling Episode-Based Payments for Cancer Using Commercial Claims Data.
Polson M; Lord T; Evangelatos T; Kangethe A; Speicher LC; Barrientos S; Zacker C
J Manag Care Spec Pharm; 2019 Feb; 25(2):235-245. PubMed ID: 30698092
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
14. Out-of-Pocket Costs Among Patients With a New Cancer Diagnosis Enrolled in High-Deductible Health Plans vs Traditional Insurance.
Fu SJ; Rose L; Dawes AJ; Knowlton LM; Ruddy KJ; Morris AM
JAMA Netw Open; 2021 Dec; 4(12):e2134282. PubMed ID: 34935922
[TBL] [Abstract][Full Text] [Related]
15. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040.
Hess LM; Cui ZL; Wu Y; Fang Y; Gaynor PJ; Oton AB
J Med Econ; 2017 Aug; 20(8):850-862. PubMed ID: 28532187
[TBL] [Abstract][Full Text] [Related]
16. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
17. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
18. A new perspective on the value of minimally invasive colorectal surgery-payer, provider, and patient benefits.
Keller DS; Senagore AJ; Fitch K; Bochner A; Haas EM
Surg Endosc; 2017 Jul; 31(7):2846-2853. PubMed ID: 27815745
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
20. Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients.
Jiang S; Hill K; Patel D; Waldeck AR; Botteman M; Aly A; Norden AD
J Med Econ; 2017 Dec; 20(12):1237-1243. PubMed ID: 28777020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
